Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.52 |
| ▸ | CA2 | P00918 | 5/20 | 0.52 |
| ▸ | CA9 | Q16790 | 5/20 | 0.52 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408805 | 0.88 | CYP2C9 (0.56) | CA12CA2CA9CA1CYP2C9 | |
| SCHEMBL406879 | 0.88 | CYP2C9 (0.56) | CA12CA2CA9CA1CYP2C9 | |
| SCHEMBL174246 | 0.84 | MAPT (0.49) | CA12CA2CA9CA1CYP2C9 | |
| SCHEMBL163647 | 0.82 | KMT2A (0.54) | CA12CA2CA9CA1CYP2C9 | |
| SCHEMBL174380 | 0.80 | TP53 (0.52) | CYP2C9HDAC4KMT2ATP53NPC1 | |
| SCHEMBL163130 | 0.78 | SMO (0.58) | CYP2C9HDAC4KMT2ATP53NPC1 | |
| SCHEMBL164651 | 0.78 | KMT2A (0.50) | CYP2C9HDAC4KMT2ATP53NPC1 | |
| SCHEMBL162572 | 0.78 | LMNA (0.49) | CYP2C9HDAC4KMT2ATP53NPC1 | |
| SCHEMBL161847 | 0.77 | NPC1 (0.49) | KMT2ATP53NPC1RAB9ANOD2 | |
| SCHEMBL161688 | 0.77 | DGAT1 (0.51) | CA12CA2CA9CA1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | CA12 4307/4885CA2 2982/4885CA9 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.